<DOC>
	<DOCNO>NCT01533324</DOCNO>
	<brief_summary>S-1 new chemotherapy drug . Some phase II trial show S-1 effective Hepatocellular Carcinoma ( HCC ) . S-1 combined calcium folinate ( SL ) show good efficiency safety colorectal cancer ( CRC ) . The short duration ( two weekly regimen ) good common course 4 week regimen tolerance . So investigators want examine efficiency safety SL one week one week regimen HCC .</brief_summary>
	<brief_title>S-1/LV One Week One Week Off Regimen Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>S-1 new chemotherapy drug . Some phase II trial show S-1 effective HCC . S-1 combine calcium folinate ( SL ) show good efficiency safety CRC . The short duration ( two weekly regimen ) good common course 4 week regimen tolerance . So investigators want examine efficiency safety SL one week one week regimen HCC . SL one week one week regimen give advanced HCC patient . The primary endpoint durable complete response ( DCR ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Formyltetrahydrofolates</mesh_term>
	<criteria>Male female , 70 year &gt; Age &gt; 18 year Patient unresectable primary hepatocellular carcinoma ChildPugh Class A B , without ascites ECOG score 0 At least one tumor nodule evaluate CT MRI Can take medicine orally Expected survival time le 12 week Women childbearing potential must negative pregnancy test perform within 7 day prior enrol portion study During trial 4 week trial , must take contraception Patients must : Hemoglobin &gt; 9.0g/dl ANC &gt; 1.5×109/L Platelet ≥ 60×109/L Total bilirubin &lt; 3mg/dl ALT AST &lt; 5 X ULN ALP &lt; 4 X ULN PTINR &lt; 2.3 Patients take Warfarin , test every week till get stable INR Serum creatinine &lt; 1.5 X ULN Serum amylase lipase &lt; 2 X ULN Known suspect allergy agent give association trial Local treatment within 4 week prior start study drug History heart disease History HIV infection except HBV HCV Active clinically serious infection ( &gt; 2 NCICTC Version 3.0 ) Clinically significant gastrointestinal bleeding within 4 week prior study entry . Embolization infarction transient ischemic disease , deep vein thrombosis , pulmonary embolization within 6 month prior study entry Previous malignancy ( except cervical carcinoma situ , adequate treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis T1 ] , early gastric cancer , malignancy curatively treat &gt; 3 year prior entry Extrahepatic tumor spread affect patient 's prognosis , bony metastasis brain metastasis Hydrothorax， ascites hydropericardium need drain Serious diarrhea Combined serious pulmonary disease , interstitial pneumonia , pulmonary fibrosis serious pulmonary emphysema Serious complication , intestinal obstruction , renal insufficiency , hepatic insufficiency cerebrovascular disorder Pregnant breastfeed Any condition unstable could jeopardize safety patient compliance study , investigator 's judgment . Gastrointestinal disease may affect absorption drug pharmacokinetics . Substance abuse , medical , psychological social condition may interfere patient 's participation study Patients unable swallow oral medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>S-1</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>fluorouracil</keyword>
</DOC>